Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2004, Pages 43-49

  Fagiolino, Pietro ^a,b  

^a Faculty of Chemistry   (Uruguay)

^b Pharmacology and Biopharmaceutics   (Uruguay)

Author keywords

Bioequivalence; Clinical pharmacokinetics; First order rate constant; Kinetic and thermodynamic factors for drug transfer

Indexed keywords

ARTICLE; BIOEQUIVALENCE; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; MATHEMATICAL ANALYSIS; STEADY STATE; THERMODYNAMICS;

EID: 2442480549     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190573     Document Type: Article

References (17)

1. Gibaldi M., Perrier D. (1982): Pharmacokinetics, Marcel Dekker, New York.
2. Redfern P., Lemmer B. (1997): Handbook of Experimental Pharmacology, Vol 125: Physiology and Pharmacology of Biological Rhytms, Springer-Verlag, Berlin Heidelberg.
3. Bruguerolle B. (1998): Chronopharmacokinetics. Current status. Clin. Pharmacokinet. 35: 83-94.
4. Ritschel W.A. (1984): Chronopharmacokinetics. Pharm. Internat. 5: 116-122.
5. Glasstone S. (1968): Tratado de Qu_mica F_sica (7_. Ed.), Aguilar S.A., Espa_a, pp. 664-666.
6. Jusko W.J. (1989): Pharmacokinetics of capacity-limited systems. J. Clin. Pharmacol. 29: 488-493.
7. Fagiolino P. (2002): The influence of cardiac output distribution on the tissue/plasma drug concentration ratio. Eur. J. Drug Metab. Pharmacokinet. 27: 79-81.
8. Fagiolino P., Wilson F., Samaniego E., V_zquez M. (2003): In vitro approach to study the influence of the cardiac output distribution on drug concentration. Eur. J. Drug Metab. Pharmacokinet. 28: 147-153.
9. Fagiolino P., Coronel J., Wilson F., Garino A. (2001): Compartmental model taking into account intravascular and extravascular sites. Proceeding of the VI Pharmatech, Recife, Brazil, 5-8 August 2001, pp. 133-134.
10. Benet L.Z. (1972): General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J. Pharm. Sci. 61: 536-541.
11. Lemmer B. (1997): Chronopharmacological aspecto of PK/PD modelling. Int. J. Clin. Pharmacol. Ther. 35: 458-464.
12. Langner B., Lemmer B. (1988): Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur. J. Clin. Pharmacol. 33: 619-624.
13. Plano I., V_zquez M., Fagiolino P. (1998): Chronopharmacokinetics of carbamazepine and its metabolite 10,11-epoxide. J. Pharm. Clin. 17: 153-156.
14. Steinijans V.W., Hauschke D., Jonkman J.H.G. (1992): Controversies in bioequivalence studies. Clin. Pharmacokinet. 22: 247-253.
15. Wilson F., Coronel J., Fagiolino P. (2001): Plasma drug monitoring in bioequivalence assessment: how accurate is it for variable drug-induced pharmacokinetic system? Proceeding of the VI Pharmatech, Recife, Brazil, 5-8 August 2001, pp. 131-132.
16. Ludden T.M., Allerheiligen S.R.B., Browne T.R., Koup J.R. (1991): Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady state phenytoin concentration. Ther. Drug Monit. 13: 120-125.
17. Conclusions of a consensus workshop, Munich, September 9, 1989. (1991): Is there a need for more precise definitions of bioavailability? Eur. J. Clin. Pharmacol. 40: 123-126.